 This study will be conducted in a randomised, double-blind, placebo-controlled design with single ascending doses of Sulforadex administered to healthy male subjects between 18 to 45 years of age. Each healthy subject will receive verbal and written information followed by signing of the Informed Consent Form ICF. 